In rhabdomyosarcoma cells, treatment with a combination of S63845 and the Bcl-xL inhibitor A-1331852 resulted in loss of MMP and activation of caspase-3, -8, and -9 [68]. This evidence concerns the gene BCL2L1 and rhabdomyosarcoma.